Academy of Medical Engineering and Translational Medicine, Tianjin University, Tianjin, China.
Tianjin Key Laboratory of Brain Science and Neural Engineering, Tianjin University, Tianjin, China.
BMC Complement Med Ther. 2022 Aug 10;22(1):216. doi: 10.1186/s12906-022-03699-7.
The traditional Chinese medicine (TCM) formula 01 for nasopharyngeal carcinoma (NPC01) is used in the management of head and neck cancers (HNCs), but whether NPC01 has an impact on the HR-QOL of patients with HNCs is unknown.
This was a retrospective study of patients with HNCs who were treated between January 2019 and January 2020 at the Head & Neck Cancer Center of Tianjin Medical University Cancer Institute & Hospital. The patients were grouped according to whether they received NPC01 or not (controls). All patients routinely completed the EORTC QLQ-C30 and QLQ-H&N35 modules before and after 3 months of systemic treatment. Health economics were collected.
The patients who received NPC01 were older than the controls (48.6 ± 11.4 vs. 43.4 ± 8.8 years, P = 0.004). All other characteristics were comparable between the two groups (all P > 0.05). In EORTC QLQ-C30, physical functioning (P = 0.03), fatigue (P = 0.04), pain (P = 0.02), appetite loss (P = 0.02), and constipation (P = 0.01) scores were improved more in the NPC01 group than in controls. In EORTC H&N35, the scores for pain (P = 0.02), swallowing (P = 0.01), and dry mouth (P = 0.02) were better in the NPC01 group than in controls. The NPC01 cost was 38.94 RMB/patient compared with 12.81 RMB/patient for regular follow-up, but considering insurance coverage, the financial burden was not higher.
The results suggest that NPC01 improves HNCs-related symptoms and HR-QOL.
中药配方 01 号（NPC01）用于治疗头颈部癌症（HNC），但 NPC01 是否会影响 HNC 患者的 HR-QOL 尚不清楚。
这是一项回顾性研究，纳入了 2019 年 1 月至 2020 年 1 月在天津医科大学肿瘤医院头颈部癌症中心接受治疗的 HNC 患者。根据患者是否接受 NPC01 治疗将其分为两组（对照组）。所有患者在接受系统治疗前和治疗后 3 个月均常规完成 EORTC QLQ-C30 和 QLQ-H&N35 模块评估。收集健康经济学数据。
接受 NPC01 治疗的患者比对照组更年长（48.6±11.4 岁 vs. 43.4±8.8 岁，P=0.004）。两组的其他特征均无显著差异（P>0.05）。在 EORTC QLQ-C30 中，NPC01 组的躯体功能（P=0.03）、疲乏（P=0.04）、疼痛（P=0.02）、食欲丧失（P=0.02）和便秘（P=0.01）评分均优于对照组。在 EORTC H&N35 中，NPC01 组的疼痛（P=0.02）、吞咽（P=0.01）和口干（P=0.02）评分均优于对照组。与常规随访相比，NPC01 的治疗费用为每位患者 38.94 元人民币，而常规随访的费用为每位患者 12.81 元人民币，但考虑到保险覆盖范围，其经济负担并未增加。
结果表明 NPC01 可改善 HNC 相关症状和 HR-QOL。
